Home | Community | Message Board

Original Seeds Store
This site includes paid links. Please support our sponsors.


Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please login or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!

Shop: OlympusMyco.com Olympus Myco Bulk Substrate   Bridgetown Botanicals Bridgetown Botanicals   Mushroom-Hut Mono Tub Substrate   Original Sensible Seeds Autoflowering Cannabis Seeds

Jump to first unread post Pages: 1
InvisibleveggieM

Registered: 07/25/04
Posts: 17,538
Alexander Shulgin's Legacy Lives On Via New Compounds And Research * 2
    #28391863 - 07/10/23 09:20 PM (10 months, 3 days ago)

Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research
July 10, 2023 - Benzinga

MAPS recent Psychedelic Science 2023 conference hosted a discussion on the newly-synthesized compounds by the organization advancing the legacy of the renowned chemist Alexander “Sasha” Shulgin’s psychedelics research legacy.

The Alexander Shulgin Research Institute (ASRI) presented findings on two new lab-created substances: ASR-3001, a second-generation, fast-acting tryptamine related to MDMA and psilocybin; and Phenylethylamine (PEA)-based non-hallucinogenic ASR-2001.

ASRI co-founder and president Dr. Nicholas Cozzi elaborated on these substances’ characterization, as well as their context within the psychedelics research field and some very interesting background history and the institute’s plans for the future, in a recent interview with Benzinga.

Inside Shulgin’s Lab: What His Heirs Are Creating

The first new compound, ASR-2001, is an orally active, non-hallucinogenic, highly potent 5-HT2A receptor activator, which demonstrated “exceptional selectivity” over the problematic (heart disease concerns) 5-HT2B receptor while not displaying any overt psychedelic effects.

It produces a “focusing-type” mental clarity state without the psychostimulant effects of drugs like Adderall or Ritalin, its 8-10 hour duration of action and lack of 5-HT2B effects making it compatible with daily dosing.

Meanwhile, ASR-3001 is a short-acting orally active compound that positively induces an internal psychedelic cognitive state, without sensory involvement. A combination the team believes makes it a potential “entry point” for patients reluctant to experiencing the fully immersive experience associated with classic psychedelics, almost like an adjunct to therapy.

While 2001’s effects are subtle, the 3001’s are noticeable, explained Cozzi. Also, as “completely different chemical structures,” both compounds have different receptor-binding profiles as well as rates of absorption: 3001’s effects are apparent within 15 minutes, while 2001’s would take between an hour and hour and a half.

ASR-2001 was explored up to 40 milligrams. With an approximate 10 to 40 milligram range, the effects -still “very subtle”- appeared at 10mg.

With ASR-3001, “the dosing range seems to be within the 8 to perhaps 14 milligrams,” says Cozzi. “And we're still doing some exploratory work, but 14 is probably on the high side, and a more agreeable or more navigable range might be in a 10 mg. So it's the same as ASR-2001 at 10 milligrams.”

The difference, again, is 2001 does not disturb and could even facilitate detailed work; while 10 mg of 3001 produces a frank psychedelic state, “so even at equal doses they produce very different effects.”

The Shulgin Research Institute is preparing corresponding studies toward IND application submissions with the FDA on both compounds and expects to commence Phase 1 clinical studies in 2024 with a licensing out option considering the costs of such trials. International protection around them will be seeked for as well.

Extras: Filter Print Post Top
Invisiblejack_straw2208
Doctor
 User Gallery


Registered: 02/12/07
Posts: 3,122
Loc: Earth
Re: Alexander Shulgin's Legacy Lives On Via New Compounds And Research [Re: veggie]
    #28392046 - 07/11/23 03:09 AM (10 months, 3 days ago)

I I wonder who will be the first to post a trip report on the shroomery!


--------------------
If you can’t tell what you desperately need, it’s probably sleep.

Extras: Filter Print Post Top
OfflineDreamStoneLFOD
 User Gallery
Registered: 07/23/21
Posts: 57
Last seen: 25 days, 16 hours
Re: Alexander Shulgin's Legacy Lives On Via New Compounds And Research [Re: veggie] * 1
    #28392176 - 07/11/23 07:34 AM (10 months, 3 days ago)

This is very EXCITING 🤘☮️🤘


--------------------
Peace🤘

Extras: Filter Print Post Top
Jump to top Pages: 1

Shop: OlympusMyco.com Olympus Myco Bulk Substrate   Bridgetown Botanicals Bridgetown Botanicals   Mushroom-Hut Mono Tub Substrate   Original Sensible Seeds Autoflowering Cannabis Seeds


Similar ThreadsPosterViewsRepliesLast post
* Shulgin Interview on Catalyst Twirling 1,218 0 10/08/03 04:44 AM
by Twirling
* Dr. Ecstasy veggieM 3,156 5 05/09/11 10:55 AM
by LuigisDeathRace
* Scientists Say Marijuana Research Blocked Redo 1,216 1 07/21/04 03:32 PM
by Redo
* Mushrooms Play a Role in Cancer Research AnnoA 816 0 04/06/04 05:08 PM
by Anno
* Shulgin on tech tv? socratesmind 3,641 2 11/20/02 07:14 AM
by Golem
* Indian researcher helping to introduce high yielding mushroo motamanM 1,339 2 11/11/03 01:03 PM
by DailyPot
* Research on Ecstasy Is Clouded by Errors cybrbeast 2,348 3 12/16/03 04:36 AM
by zeta
* American research therapeutic value of XTC stefan 2,436 5 11/28/03 09:58 AM
by DailyPot

Extra information
You cannot start new topics / You cannot reply to topics
HTML is disabled / BBCode is enabled
Moderator: motaman, veggie, Alan Rockefeller, Mostly_Harmless
338 topic views. 0 members, 2 guests and 2 web crawlers are browsing this forum.
[ Show Images Only | Sort by Score | Print Topic ]
Search this thread:

Copyright 1997-2024 Mind Media. Some rights reserved.

Generated in 0.019 seconds spending 0.005 seconds on 15 queries.